Singapore: Efficient resource to therapy of complex disorders with lesser side-effects has accelerated growth of monoclonal antibodies based therapeutics against conventional chemical drugs.

However, high developmental costs constitute a major barrier for mid-segment market entrants. Growing market opportunities generated by innovative treatment methods and existing product success rate will boost market growth.

New analysis from Frost & Sullivan, Analysis of the Therapeutic Monoclonal Antibodies Market in Europe, finds that the market earned revenues of $19.01 billion in 2011 and estimates this to reach $42.37 billion in 2018, at a compound annual growth rate (CAGR) of 12.1% from 2011-2018.

Monoclonal antibodies (mAbs) are mono-specific high molecular weight complex proteins that are capable of post translational modifications, such as glycosylation. They are commonly used biologics for therapeutics and therefore are the fastest growing segment within the biotechnology market.

mAbs are predominantly used in the treatment of cancer and autoimmune and inflammatory disorders. Other therapy areas using mAbs include cardiovascular and infectious diseases, as well as organ transplants.